Refine
Document Type
- Journal article (1244)
- Conference proceeding (1039)
- Book chapter (381)
- Book (223)
- Doctoral Thesis (54)
- Working Paper (38)
- Anthology (32)
- Report (25)
- Patent / Standard / Guidelines (24)
- Issue of a journal (19)
Is part of the Bibliography
- yes (3088)
Institute
- ESB Business School (1107)
- Informatik (875)
- Technik (509)
- Life Sciences (343)
- Texoversum (220)
- Zentrale Einrichtungen (16)
Publisher
- Springer (473)
- IEEE (252)
- Elsevier (243)
- Hochschule Reutlingen (191)
- MDPI (99)
- Wiley (72)
- Gesellschaft für Informatik e.V (69)
- Universität Tübingen (65)
- De Gruyter (60)
- VDE Verlag (48)
Virtual prototyping of integrated mixed-signal smart-sensor systems requires high-performance co-simulation of analog frontend circuitry with complex digital controller hardware and embedded real-time software. We use SystemC/TLM 2.0 in combination with a cycle-count accurate temporal decoupling approach to simulate digital components and firmware code execution at high speed while preserving clock cycle accuracy and, thus, real-time behavior at time quantum boundaries. Optimal time quanta ensuring real-time capability can be calculated and set automatically during simulation if the simulation engine has access to exact timing information about upcoming communication events. These methods fail in case of non-deterministic, asynchronous events resulting in a possibly invalid simulation result. In this paper, we propose an extension of this method to the case of asynchronous events generated by blackbox sources from which a-priori event timing information is not available, such as coupled analog simulators or hardware in the loop. Additional event processing latency and/or rollback effort caused by temporal decoupling is minimized by calculating optimal time quanta dynamically in a SystemC model using a linear prediction scheme. For an example smart-sensor system model, we show that quasi- periodic events that trigger activities in temporally decoupled processes are handled accurately after the predictor has settled.
An ultra-low power capacitance extrema and ratio detector for electrostatic energy harvesters
(2015)
The power supply is one of the major challenges for applications like internet of things IoTs and smart home. The maintenance issue of batteries and the limited power level of energy harvesting is addressed by the integrated micro power supply presented in this paper. Connected to the 120/230 Vrms mains, which is one of the most reliable energy sources and anywhere indoor available, it provides a 3.3V DC output voltage. The micro power supply consists of a fully integrated ACDC and DCDC converter with one external low voltage SMD buffer capacitor. The micro power supply is fabricated in a low cost 0.35 μm 700 V CMOS technology and covers a die size of 7.7 mm2. The use of only one external low voltage SMD capacitor, results in an extremely compact form factor. The ACDC is a direct coupled, full wave rectifier with a subsequent bipolar shunt regulator, which provides an output voltage around 17 V. The DCDC stage is a fully integrated 4:1 SC DCDC converter with an input voltage as high as 17 V and a peak efficiency of 45 %. The power supply achieves an overall output power of 3 mW, resulting in a power density of 390 μW/mm2. This exceeds prior art by a factor of 11.
The EU funded project RobLog recently developed a system able to autonomously unload coffee sacks from a standard container. Being the first of its kind, a further development is needed in order for the system to be competitive against manual labor. Financing this development entails a risk, hence a justified skepticism, which can be overcome by the longsighted view of the existing market potential. This paper presents a method to estimate the market potential of autonomous unloading systems for heavy deformable goods. Starting from the analysis of the coffee trade, first the current coffee traffic is investigated in order to calculate the number of autonomous systems needed to handle the imported sacks; Results are validated and the method is extended for the calculation of the potential of other market segments, where the same unloading technology can be applied.
According to a recent survey the great majority of players in logistics are planning to adopt one or more robotic solutions until 2019. Technical solutions for automation of processes in logistics are often available as a market-ready product, but the lack of standardization and skepticism towards long term investments are often the reasons why these solutions are not implemented on a large scale. This paper is set to bridge the gap between the world of technologies and the one of applications in order to help investors, robot producers and system integrators to decide on which branch of logistics to set their focus. The three main branches Courier Express Parcel (CEP), contract logistics and production logistics are briefly defined and distinguished through their characteristic factors and parameters. Then a method based on the analysis of three parameters (operative costs, required performance and flexibility) in the three branches is set to identify the most convenient branch of logistics for investing in new technologies, namely the one in which the risk of investment is lower, the return is higher and faster. The conclusion of the method shows that higher labor costs, strict regulations and higher standardization make the production logistics the most suitable branch for investments in emerging automation solutions.
As long as there have been professional sports, there have been relationships on different levels. For example, sponsorship (or patronage as it was called in the early days) was mostly based on personal relations between the local benefactors and their favourite sports club. Regarding media, clubs always maintained special relationships with selected journalists. The bond between fans and their clubs was always a close and mutually beneficial one. All these relationships existed from the start of the sports business. Therefore, relationship marketing is nothing new in the context of sports. Many sporting organisations always knew to value a deep and good relationship with their stakeholders and practised relationship marketing without being aware of it. Successful sports managers, however, take the old wisdom and turn it into a modern relationship marketing approach by structuring the various relationships in order to make them more effective and profitable for the own sporting organisation and the various stakeholders. This chapter ... illustrates the many facets of relationship marketing and the possibilities it offers in the context of the sports business.
For many companies, it is major international sporting events (in particular the Football World Cup or the Olympic Games) that constitute the ideal platform for the integration of their target group-specific marketing communication into an attractive sports environment. Sports event organizers sell exclusive marketing rights for their events to official sponsors, who, in return, acquire exclusive options to utilize the event for their own advertising purposes. Ambush marketing is the method used by companies that do not hold marketin rights to an event, but still use their marketing activities in diverse ways to establish a connection to it. There is still whidespread debate and confusion about the topic. Ambush marketing is often defined in different ways, by different people, according to their position as either supporters of opponents of the practice.
In this paper it is first identified the trade-off among costs, flexibility and performances of autonomous robotic solutions for material handling processes, where adding value with automation is not as trivial as in production processes: hence the requirement for automated solutions to be simple, lean and efficient becomes even stricter. Then a method for modelling and comparing differential performances and costs of manual and autonomous solutions is developed. As a result of the method, a smart man-machine collaborative interface is designed and its impact evaluated on a specific case of study. Results are then generalized and prove the strong conclusions that in unconstrained environments, where full standardization cannot be achieved, the risk of investing in autonomous solutions can only be mitigated by creating a fast and smart man-machine collaborative interface.
Management nowadays is confronted by a variety of information originating from either internal or external sources. Thereby, the difficulty to focus on the relevant and company critical keyfigures information increases. In practice, information management is often a major weakness of efficient corporate management. That weakness is caused by the lack of a centralized, categorized and summarized presentation and analysis of strategy and decision-relevant information. Management cockpits, a kind of information center for managers, are an approach to meet the challenges of information management. They are a specific work environment for decision makers to get a quick and simple overview of the company’s economic situation. In the most completely equipped premises, the entire process is supported - from acquiring information, to analysis, decision-making, and communication. Use of management cockpits, a cross-functional, KPI-based and strategyoriented controlling and management process, can be successfully established in companies as well as the work of interdisciplinary management teams, which are supported. In order to provide these possibilities, the management cockpit is equipped with a range of functionalities that allow the structuring, categorization and management-adequate visualization of information along with extensive analysis and simulation options. Management cockpits, as a communication and collaboration platform, are a starting point and valuable process companion on the way to holistic and sustainable performance management.
Informationstechnische Systeme, die den Arbeitsablauf im klinischen Bereich unterstützen, sind aktuell auf organisatorische Abläufe beschränkt. Diese Arbeit stellt einen ersten Ansatz vor, wie solch ein System in den perioperativen Bereich eingebracht werden kann. Hierzu wurde eine Workflow Engine mit einer perioperativen Prozess-Visualisierung verknüpft. Das System wurde nach Modell-View-Controller-Prinzip implementiert. Als "Controller" kommt die Workflow Engine zum Einsatz; also "Modell" ein Prozessmodell, mit den erforderlichen klinischen Daten. Der "View" wurde durch eine abgekoppelte Anwendung realisiert, welche auf Web-Technologien basiert. Drei Visualisierungen, die Workflow Engine sowie die Anbindung beider über eine Datenbankschnittstelle, wurden erfolgreich umgesetzt. Bei den drei Visualisierungen wurden jeweils eine Ansicht für den OP-Koordinator, den Springer und eine Ansicht für die Übersicht einer OP erstellt.
An operating room is a stressful work environment. Nevertheless, all involved persons have to work safely as there is no space for mistakes. To ensure a high level of concentration and seamless interaction, all involved persons have to know their own tasks and the tasks of their colleagues. The entire team must work synchronously at all times. To optimize the overall workflow, a task manager supporting the team was developed. In parallel, a common conceptual design of a business process visualization was developed, which makes all relevant information accessible in real-time during a surgery. In this context an overview of all processes in the operating room was created and different concepts for the graphical representation of these user-dependent processes were developed. This paper describes the concept of the task manager as well as the general concept in the field of surgery.
Im Rahmen der Vernetzung des Autos drängen neue Wettbewerber in die Automobilindustrie. Mittels disruptiver Innovationsmethoden haben Google, Apple, Facebook und Co. bereits Branchen grundlegend verändert und Marktführer wie Nokia oder Otto innerhalb weniger Jahre abgelöst. Die folgende Arbeit befasst sich mit diesen Methoden und der Fragestellung, wie sie in den automotiven Produktentstehungsprozess integriert werden können, um nachhaltig erfolgreiche Geschäftsmodelle am Markt platzieren zu können.
In recent years, the rise of the digital transformation received significant importance in Business-to-Business (B2B) research. Social media applications provide executives with a raft of new options. Consequently, interfaces to social media platforms have also been integrated into B2B salesforce applications, although very little is as yet known about their usage and general impact on B2B sales performance. This paper evaluates 1) the conceptualization of social media usage in a dyadic B2B relationship; 2) the effects of a more differentiated usage construct on customer satisfaction; 3) antecedents of social media usage on multiple levels; and 4) the effectiveness of social media usage for different types of customers. The framework presented here is tested cross-industry against data collected from dyadic buyer seller relationships in the IT service industry. The results elucidate the preconditions and the impact of social media usage strategies in B2B sales relations.
The efficiency of pharmaceutical research and development (R&D) reflected by increasing costs of R&D, long timelines, and low probabilities of technical and regulatory success decreased continuously in the past years. Today, the costs for discovering and developing a new drug are enormously high with more than USD 2 billion per new molecular entity (NME), while the average overall success of a research project to provide an NME is in the single-digit percentage rate, and the total timelines of R&D easily exceeds 10 years questioning the return on investment (ROI) of pharmaceutical R&D. As a consequence and also caused by numerous patent expirations of blockbuster drugs that increased the pressure to return to an acceptable ROI, the pharmaceutical industry addressed this challenge and the related causes and identified several actions that need to be taken to increase the output/input ratio of R&D. This book chapter will review the pipeline sizes and the R&D investments of multinational pharmaceutical companies, will describe new processes that have been implemented to increase the reach and to reduce costs of pharmaceutical R&D, and it will illustrate new innovation models that were developed to increase the R&D efficiency.
The reduced research and development (R&D) efficiency, strong competition from generics, increased cost pressure from payers, and an increased biological complexity of new target indications have resulted in a rethinking and a change from a traditional and more closed R&D model in the pharmaceutical industry toward the new paradigm of open innovation. In the past years, pharmaceutical companies have broadened their external networks toward research collaborations with academic institutes, technology providers, or codevelopment partners. To fulfill the demand to reduce timelines and costs, research-based pharmaceutical companies started to outsource R&D activities. In addition, internal R&D processes were adjusted to the more open R&D model and new processes such as alliance management were established. The corporate frontier of pharmaceutical companies became permeable and more open. As a result, the focus of pharmaceutical R&D expanded from a purely internal toward a mixed internal and external model. Today, the U.S. pharmaceutical company Eli Lilly may have established the most open model toward external innovation, as it has integrated its innovation processes with its business model. Other companies are following this more open R&D model with newer concepts such as new frontier sciences, drug discovery alliances, private public partnerships, innovation incubators, virtual R&D, crowdsourcing, open source innovation, and innovation camps.
Clinical development is historically the phase in which a potential new medicine is being tested in phase 2 and phase 3 patient trials to demonstrate the new molecules' efficacy and safety to support the regulatory approval of drugs by health authorities. This relatively focused approach has been considerably expanded by a number of forces from within the pharmaceutical industry and equally important by changes in the healthcare systems. The need to identify the optimal patient population, showstoppers leading to discontinuation of clinical programs, the silent but constant removal of surrogate endpoints for registration, and the increased demand for real-life data which are used to demonstrate the patients' benefit and which have an ever-increasing role for pricing and reimbursement negotiations are today an integral part of this phase.
This chapter will review both the nuts and bolts of clinical development but also recent developments in this area which shape the environment and how the different players have reacted and what options might need to be explored in the future.
It is known that the costs related with drug research and development (R&D) and the timelines to develop a new drug increased over the past years. In parallel, the success rates of drug projects along the pharmaceutical R&D phases are still very low, and the outcome of all R&D efforts is stagnating. In consequence, the R&D efficiency defined as the financial investment per drug has been steadily decreasing. As innovation is the major growth driver of the pharmaceutical industry, reliable data on R&D efficiency and new concepts to overcome these challenges are of great interest for R&D managers and the sustainability of the pharmaceutical industry as a whole. This book chapter reviews publications on R&D performance indicators of the past years, such as the success rates and timelines per phase. Additionally, it illustrates the factors influencing the success rates, timelines, and costs of pharmaceutical R&D most and, thus, the denominators of the R&D efficiency.
This practical guide for advanced students and decision-makers in the pharma and biotech industry presents key success factors in R&D along with value creators in pharmaceutical innovation. A team of editors and authors with extensive experience in academia and industry and at some of the most prestigious business schools in Europe discusses in detail the innovation process in pharma as well as common and new research and innovation strategies. In doing so, they cover collaboration and partnerships, open innovation, biopharmaceuticals, translational medicine, good manufacturing practice, regulatory affairs, and portfolio management. Each chapter covers controversial aspects of recent developments in the pharmaceutical industry, with the aim of stimulating productive debates on the most effective and efficient innovation processes. A must-have for young professionals and MBA students preparing to enter R&D in pharma or biotech as well as for students on a combined BA/biomedical and natural sciences program.
Im Fokus der Arbeit steht die Unterstützung der Stentgraftauswahl bei endovaskulärer Versorgung eines infrarenalen Aortenaneurysmas. Im Rahmen der Arbeit wurde eine Methode zur Auswertung von Ergebnissen einer Finite Elemente-Analyse zum Stentgraftverhalten konzipiert, implementiert und im Rahmen einer deutschlandweiten Benutzerstudie mit 16 Chirurgen diskutiert. Die entwickelte Mensch-Maschine-Schnittstelle ermöglicht dem Gefäßmediziner eine interaktive Analyse berechneter Fixierungskräfte und Kontaktzustände mehrerer Stentgrafts im Kontext mit dem zu behandelnden Aortenabschnitt. Die entwickelte Methode ermöglicht eine tiefergehende Auseinandersetzung der Mediziner mit numerischen Simulationen und Stentgraftbewertungsgrößen. Hierdurch konnte im Rahmen der Benutzerstudie das Einsatzpotenzial numerischer Simulationen zur Unterstützung der Stentgraftauswahl ermittelt und eine Anforderungsspezifikation an ein System zur simulationsbasierten Stentgraftplanung definiert werden. Im Ergebnis wurde als wesentliches Einsatzpotenzial die Festlegung eines Mindestmaßes an Überdimensionierung, die Optimierung der Schenkellänge von bifurkativen Stentgrafts sowie der Vergleich unterschiedlicher Stentgraftdesigns ermittelt. Zu den wesentlichen Funktionen eines Systems zur simulationsbasierten Stentgraftauswahl gehören eine Übersichtskarte zu farbkodiertem Migrationsrisiko pro Stentgraft und Landungszone, die Visualisierung des Abdichtungszustandes der Stentkomponenten sowie die Darstellung von Stentgraft- und Gefäßdeformationen im 3D-Modell.
Die steigende Personalisierbarkeit von Produkten fuhrt zu einem wachsenden Variantenspektrum in der Fertigung. Nicht zuletzt aufgrund der damit einhergehenden Produktionskomplexität und den hohen Wandlungsanforderungen an die Montage werden viele komplexe Stückgüter weiterhin überwiegend manuell montiert. Visuelle Assistenzsysteme geben den Mitarbeitern die nötige Handlungsunterstützung, wenn kein Produkt dem anderen gleicht und damit das Fehlerpotenzial steigt.